Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Cameron

Showing results (831-840 of 865) with videos related to

Pageof 87
Sort By:
Blood Advances|September 15, 2021
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceGuillaume Richard-Carpentier, Hagop M Kantarjian, Guilin Tang, et al.
Cancers|November 13, 2025
Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute LeukemiaChi Young Ok, Guilin Tang, Sanam Loghavi, et al.
Human Molecular Genetics|October 11, 2019
ADAMTS9 and ADAMTS20 are differentially affected by loss of B3GLCT in mouse model of Peters plus syndromeBernadette C Holdener, Christopher J Percival, Richard C Grady, et al.
Human Molecular Genetics|June 14, 2020
Corrigendum to: ADAMTS9 and ADAMTS20 are differentially affected by loss of B3GLCT in mouse model of Peters plus syndromeBernadette C Holdener, Christopher J Percival, Richard C Grady, et al.
Cancer|October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseGhayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
American Journal of Hematology|December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitorNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Nature Climate Change|June 12, 2026
A fixed methane filter maximizes freshwater emissions under warmingSarah F Harpenslager, Kate Randall, Yizhu Zhu, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|December 25, 2024
Ischemic stroke prevention in patients with atrial fibrillation and a recent ischemic stroke, TIA, or intracranial hemorrhage: A World Stroke Organization (WSO) scientific statementLuciano A Sposato, Alan C Cameron, Michelle C Johansen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 29, 2023
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel TherapiesFatima Zahra Jelloul, Andres E Quesada, Richard K Yang, et al.
Pageof 87

Showing results (831-840 of 865) with videos related to

Sort By:
Pageof 87
Blood Advances|September 15, 2021
Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experienceGuillaume Richard-Carpentier, Hagop M Kantarjian, Guilin Tang, et al.
Cancers|November 13, 2025
Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute LeukemiaChi Young Ok, Guilin Tang, Sanam Loghavi, et al.
Human Molecular Genetics|October 11, 2019
ADAMTS9 and ADAMTS20 are differentially affected by loss of B3GLCT in mouse model of Peters plus syndromeBernadette C Holdener, Christopher J Percival, Richard C Grady, et al.
Human Molecular Genetics|June 14, 2020
Corrigendum to: ADAMTS9 and ADAMTS20 are differentially affected by loss of B3GLCT in mouse model of Peters plus syndromeBernadette C Holdener, Christopher J Percival, Richard C Grady, et al.
Cancer|October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseGhayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
American Journal of Hematology|December 23, 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitorNicholas J Short, Hagop M Kantarjian, Koji Sasaki, et al.
The Lancet. Oncology|October 4, 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 studyElias Jabbour, Hagop Kantarjian, Farhad Ravandi, et al.
Nature Climate Change|June 12, 2026
A fixed methane filter maximizes freshwater emissions under warmingSarah F Harpenslager, Kate Randall, Yizhu Zhu, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|December 25, 2024
Ischemic stroke prevention in patients with atrial fibrillation and a recent ischemic stroke, TIA, or intracranial hemorrhage: A World Stroke Organization (WSO) scientific statementLuciano A Sposato, Alan C Cameron, Michelle C Johansen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 29, 2023
Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel TherapiesFatima Zahra Jelloul, Andres E Quesada, Richard K Yang, et al.
Pageof 87